Tolvaptan
Active ingredient: Tolvaptan
In short: Tolvaptan is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate
What is Tolvaptan used for?
Tolvaptan is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
Limitations of Use
Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan.
It has not been established that raising serum sodium with tolvaptan provides a symptomatic benefit to patients.
β Boxed warning (FDA's strongest warning)
(A) Initiate and re-initiate in a hospital and monitor serum sodium
Tolvaptan should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely.
Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.
(B) Not for use for autosomal dominant polycystic kidney disease (ADPKD)
Because of the risk of hepatotoxicity, tolvaptan should not be used for ADPKD outside of the FDA-approved REMS
Tolvaptan dosage
Patients should be in a hospital for initiation and re-initiation of therapy to evaluate the therapeutic response and because too rapid correction of hyponatremia can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death.
The usual starting dose for tolvaptan is 15 mg administered once daily without regard to meals. Increase the dose to 30 mg once daily, after at least 24 hours, to a maximum of 60 mg once daily, as needed to achieve the desired level of serum sodium. Do not administer tolvaptan for more than 30 days to minimize the risk of liver injury .
During initiation and titration, frequently monitor for changes in serum electrolytes and volume. Avoid fluid restriction during the first 24 hours of therapy. Patients receiving tolvaptan should be advised that they can continue ingestion of fluid in response to thirst .
Following discontinuation from tolvaptan, patients should be advised to resume fluid restriction and should be monitored for changes in serum sodium and volume status.
How to take Tolvaptan β instructions & advice from the label
As a part of patient counseling, healthcare providers must review the tolvaptan tablets Medication Guide with every patient .
Pregnancy
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy .
Lactation
Advise patients not to breastfeed an infant if they are taking tolvaptan tablets .
Rx Only
APOTEX INC.
Tolvaptan Tablets 15 mg and 30 mg
Manufactured by: | Manufactured for:
Apotex Inc. Toronto, Ontario, Canada M9L 1T9 | Apotex Corp. Weston, Florida 33326
Rev. 4
Warnings & precautions
Do not take this medicine if: Tolvaptan is contraindicated in the following conditions:
Patients with autosomal dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS
Unable to sense or respond to thirst
Hypovolemic hyponatremia
Taking strong CYP3A inhibitors
Anuria
Hypersensitivity (e.g., anaphylactic shock, rash generalized) to tolvaptan or any components of the product
Osmotic demyelination syndrome is a risk associated with too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours). Osmotic demyelination results in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma or death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable. In controlled clinical trials in which tolvaptan was administered in titrated doses starting at 15 mg once daily, 7% of tolvaptan-treated subjects with a serum sodium <130 mEq/L had an increase in serum sodium greater than 8 mEq/L at approximately 8 hours and 2% had an increase greater than 12 mEq/L at 24 hours. Approximately 1% of placebo-treated subjects with a serum sodium <130 mEq/L had a rise greater than 8 mEq/L at 8 hours and no patient had a rise greater than 12 mEq/L/24 hours. Osmotic demyelination syndrome has been reported in association with tolvaptan therapy . Patients treated with tolvaptan should be monitored to assess serum sodium concentrations and neurologic status, especially during initiation and after titration. Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving tolvaptan who develop too rapid a rise in serum sodium, discontinue or interrupt treatment with tolvaptan and consider administration of hypotonic fluid. β¦
Tolvaptan side effects
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse event information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
In multiple-dose, placebo-controlled trials, 607 hyponatremic patients (serum sodium <135 mEq/L) were treated with tolvaptan. The mean age of these patients was 62 years; 70% of patients were male and 82% were Caucasian. One hundred eighty-nine (189) tolvaptan-treated patients had a serum sodium <130 mEq/L, and 52 patients had a serum sodium <125 mEq/L. Hyponatremia was attributed to cirrhosis in 17% of patients, heart failure in 68% and SIADH/other in 16%. Of these patients, 223 were treated with the recommended dose titration (15 mg titrated to 60 mg as needed to raise serum sodium).
Overall, over 4,000 patients have been treated with oral doses of tolvaptan in open-label or placebo-controlled clinical trials. Approximately 650 of these patients had hyponatremia; approximately 219 of these hyponatremic patients were treated with tolvaptan for 6 months or more. β¦
Drug interactions
Strong CYP3A Inhibitors
Tolvaptan AUC was 5.4 times as large and Cmax was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole . Larger doses of the strong CYP3A inhibitor would be expected to produce larger increases in tolvaptan exposure. Concomitant use of tolvaptan with strong CYP3A inhibitors is contraindicated .
Moderate CYP3A Inhibitors
A substantial increase in the exposure to tolvaptan would be expected when tolvaptan tablets are co-administered with moderate CYP3A inhibitors. Avoid co-administration of tolvaptan tablets with moderate CYP3A inhibitors .
Patients should avoid grapefruit juice beverages while taking tolvaptan tablets .
Strong CYP3A Inducers
Co-administration of tolvaptan tablets with strong CYP3A inducers reduces exposure to tolvaptan tablets . Avoid concomitant use of tolvaptan tablets with strong CYP3A inducers.
Although specific interaction studies were not performed, in clinical studies tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. β¦
About this medicine
Tolvaptan tablets contain tolvaptan, a selective vasopressin V2-receptor antagonist in tablets for oral use available in 15 mg or 30 mg strengths. Tolvaptan is 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine. The empirical formula is C26H25ClN2O3. Molecular weight is 448.95 g/mol. The chemical structure is:
Tolvaptan tablets for oral use contain 15 mg or 30 mg of tolvaptan. Inactive ingredients include anhydrous lactose, colloidal silicon dioxide, copovidone, croscarmellose sodium, indigotine al lake 12-14% and magnesium stearate.
How it works: Tolvaptan is a selective vasopressin V2-receptor antagonist with an affinity for the V2-receptor that is 1.8 times that of native arginine vasopressin (AVP). Tolvaptan affinity for the V2-receptor is 29 times greater than for the V1a-receptor. β¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d9fd11d0-4269-12fb-95cf-b3c11d75e479. Read the full official label on DailyMed.
Related medicines
Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol